# A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

> **NCT02399137** · PHASE2 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 88 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** MM-141
- **DRUG:** Placebo
- **DRUG:** Gemcitabine
- **DRUG:** Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT02399137
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399137, "A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02399137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*